1. Home
  2. UTSI vs CTXR Comparison

UTSI vs CTXR Comparison

Compare UTSI & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UTSI
  • CTXR
  • Stock Information
  • Founded
  • UTSI 1991
  • CTXR 2007
  • Country
  • UTSI China
  • CTXR United States
  • Employees
  • UTSI N/A
  • CTXR N/A
  • Industry
  • UTSI Telecommunications Equipment
  • CTXR Biotechnology: Pharmaceutical Preparations
  • Sector
  • UTSI Telecommunications
  • CTXR Health Care
  • Exchange
  • UTSI Nasdaq
  • CTXR Nasdaq
  • Market Cap
  • UTSI 24.9M
  • CTXR 20.8M
  • IPO Year
  • UTSI 2000
  • CTXR N/A
  • Fundamental
  • Price
  • UTSI $2.28
  • CTXR $1.18
  • Analyst Decision
  • UTSI
  • CTXR Strong Buy
  • Analyst Count
  • UTSI 0
  • CTXR 3
  • Target Price
  • UTSI N/A
  • CTXR $53.00
  • AVG Volume (30 Days)
  • UTSI 6.0K
  • CTXR 453.7K
  • Earning Date
  • UTSI 08-29-2025
  • CTXR 08-12-2025
  • Dividend Yield
  • UTSI N/A
  • CTXR N/A
  • EPS Growth
  • UTSI N/A
  • CTXR N/A
  • EPS
  • UTSI N/A
  • CTXR N/A
  • Revenue
  • UTSI $9,793,000.00
  • CTXR N/A
  • Revenue This Year
  • UTSI N/A
  • CTXR N/A
  • Revenue Next Year
  • UTSI N/A
  • CTXR $851.67
  • P/E Ratio
  • UTSI N/A
  • CTXR N/A
  • Revenue Growth
  • UTSI N/A
  • CTXR N/A
  • 52 Week Low
  • UTSI $1.84
  • CTXR $0.65
  • 52 Week High
  • UTSI $3.22
  • CTXR $15.25
  • Technical
  • Relative Strength Index (RSI)
  • UTSI 44.88
  • CTXR 43.14
  • Support Level
  • UTSI $2.15
  • CTXR $1.13
  • Resistance Level
  • UTSI $2.55
  • CTXR $1.25
  • Average True Range (ATR)
  • UTSI 0.15
  • CTXR 0.08
  • MACD
  • UTSI -0.03
  • CTXR -0.00
  • Stochastic Oscillator
  • UTSI 19.21
  • CTXR 17.02

About UTSI UTStarcom Holdings Corp.

UTStarcom Holdings Corp is providing telecommunication network products, solutions and services. It focus on delivering carrier-class packet optical, network synchronization and broadband access (both wireless and fixed line) products and solutions, coupled with Software Defined Networking (SDN) platform, optimized for mobile backhaul, metro aggregation, broadband access and value added services. The business activity of the firm is operated through the Equipment and Service segment. The Equipment segment is focused on equipment sales, including network infrastructure and application products, and the Service segment is engaged in providing services and support of equipment products and also the new operational support. Key revenue is generated from Equipment segment.

About CTXR Citius Pharmaceuticals Inc.

Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.

Share on Social Networks: